» Articles » PMID: 32639876

Meta-Analysis of Prevalence of Triple-Negative Breast Cancer and Its Clinical Features at Incidence in Indian Patients With Breast Cancer

Overview
Journal JCO Glob Oncol
Specialty Oncology
Date 2020 Jul 9
PMID 32639876
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Breast cancer is the most common cancer in women in India, with higher incidence rates of aggressive subtypes, such as triple-negative breast cancer (TNBC).

Methods: A systematic review was performed to compute pooled prevalence rates of TNBC among patients with breast cancer, and clinical features at presentation were systematically compared with non-TNBC in an Indian cohort of 20,000 patients.

Results: Combined prevalence of TNBC among patients with breast cancer was found to be on the higher side (27%; 95% CI, 24% to 31%). We found that the estrogen receptor (ER) expression cutoff used to determine ER positivity had an influence on the pooled prevalence and ranged from 30% (ER/progesterone receptor [PR] cut ff at 1%) to 24% (ER/PR cutoff at 10%). Odds for TNBC to present in the younger age-group were significantly higher (pooled odds ratio [OR], 1.35; 95% CI, 1.08 to 1.69), with a significantly younger mean age of incidence (weighted mean difference, -2.75; 95% CI, -3.59 to -1.92). TNBC showed a significantly higher odds of presenting with high grade (pooled OR, 2.57; 95% CI, 2.12 to 3.12) and lymph node positivity (pooled OR, 1.39; 95% CI, 1.21 to 1.60) than non-TNBC.

Conclusion: Systematic review and meta-analysis of 34 studies revealed a high degree of heterogeneity in prevalence of TNBC within Indian patients with breast cancer, yet pooled prevalence of TNBC is high in India. High proportions of patients with TNBC present with aggressive features, such as high grade and lymph node positivity, compared with patients without TNBC. We emphasize the need for standardized methods for accurate diagnosis in countries like India.

Citing Articles

Molecular subtyping and target identification in triple negative breast cancer through immunohistochemistry biomarkers.

Bouzid R, Bouzid R, Labed H, Serhani I, Hellal D, Oumeddour L BMC Cancer. 2025; 25(1):454.

PMID: 40082760 PMC: 11905517. DOI: 10.1186/s12885-025-13832-7.


A phase II, randomized, open-labeled study to evaluate low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer (TNBC).

Arora A, Seenu V, Parshad R, Bansal V, Dhar A, Mathur S Trials. 2025; 26(1):73.

PMID: 40011935 PMC: 11866667. DOI: 10.1186/s13063-025-08726-9.


Prioritizing cases from a multi-institutional cohort for a dataset of pathologist annotations.

Garcia V, Gardecki E, Jou S, Li X, Shroyer K, Saltz J J Pathol Inform. 2024; 16:100411.

PMID: 39720416 PMC: 11667696. DOI: 10.1016/j.jpi.2024.100411.


Continental differences in the association between excess body weight and prognosis in triple-negative breast cancer: a meta-analysis.

Vaz-Goncalves L, Protani M, Saunus J, Colditz G, Reeves M Breast Cancer Res Treat. 2024; 209(2):215-227.

PMID: 39476311 DOI: 10.1007/s10549-024-07538-w.


Uncovering novel pathogenic variants and pathway mutations in triple-negative breast cancer among the endogamous mizo tribe.

Pachuau L, Lalremmawia H, Ralte L, Vanlalpeka J, Pautu J, Chenkual S Breast Cancer Res Treat. 2024; 209(2):375-387.

PMID: 39384723 DOI: 10.1007/s10549-024-07501-9.


References
1.
Plasilova M, Hayse B, Killelea B, Horowitz N, Chagpar A, Lannin D . Features of triple-negative breast cancer: Analysis of 38,813 cases from the national cancer database. Medicine (Baltimore). 2016; 95(35):e4614. PMC: 5008562. DOI: 10.1097/MD.0000000000004614. View

2.
Urru S, Gallus S, Bosetti C, Moi T, Medda R, Sollai E . Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients. BMC Cancer. 2018; 18(1):56. PMC: 5759886. DOI: 10.1186/s12885-017-3969-y. View

3.
Zubeda S, Kaipa P, Shaik N, Mohiuddin M, Vaidya S, Pavani B . Her-2/neu status: a neglected marker of prognostication and management of breast cancer patients in India. Asian Pac J Cancer Prev. 2013; 14(4):2231-5. DOI: 10.7314/apjcp.2013.14.4.2231. View

4.
Dogra A, Chandra Doval D, Sardana M, Chedi S, Mehta A . Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India. Asian Pac J Cancer Prev. 2015; 15(24):10577-83. DOI: 10.7314/apjcp.2014.15.24.10577. View

5.
Alcantara V, Lim G, Lim S, Sultana R, Lee J . Incidence and prognosis of non-metastatic triple negative breast cancer (TNBC) among different races in Southeast Asia. J Surg Oncol. 2017; 115(5):523-537. DOI: 10.1002/jso.24559. View